Drug Interaction Report
4 potential interactions and/or warnings found for the following 2 drugs:
- avanafil
- Entresto (sacubitril / valsartan)
Interactions between your drugs
valsartan avanafil
Applies to: Entresto (sacubitril / valsartan), avanafil
Avanafil can add to the blood pressure-lowering effect of valsartan. Contact your doctor if you experience signs and symptoms of low blood pressure such as dizziness, lightheadedness, fainting, flushing, headache, or a rapid pulse or heart rate. You may be more likely to experience these problems at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
avanafil sacubitril
Applies to: avanafil, Entresto (sacubitril / valsartan)
Consumer information for this interaction is not currently available.
MONITOR: Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications, including vasodilators. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation and thus blood pressure (BP) reduction. For example, when sildenafil (100 mg) was coadministered with amlodipine (5 mg or 10 mg) to hypertensive patients, the mean additional reduction in supine BP was 8/7 mmHg. Likewise, in a group of patients whose hypertension was controlled with nifedipine slow-release (30 mg or 60 mg) once daily, the addition of vardenafil (20 mg) produced a mean additional supine BP reduction of 6/5 mmHg compared to placebo. When coadministered with amlodipine (5 mg) daily or enalapril (20 mg) daily, a single dose of avanafil (200 mg) produced a mean maximum decrease in supine systolic BP of 1.2 mmHg (amlodipine) and supine BP of 1.8/3.5 mmHg (enalapril) compared to placebo.
MANAGEMENT: Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.
Drug and food interactions
valsartan food
Applies to: Entresto (sacubitril / valsartan)
If you are taking valsartan you should avoid potassium-containing salt substitutes or over-the-counter potassium supplements without first talking to your doctor. This can cause high levels of potassium in your blood. High levels of potassium can cause weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs. Call your doctor at once if you have any of these symptoms.
avanafil food
Applies to: avanafil
Avanafil can lower blood pressure, and combining it with alcohol may further increase this effect. You may be more likely to experience symptoms such as dizziness, lightheadedness, fainting, flushing, headache, and heart palpitations. You should avoid or limit the use of alcohol while being treated with avanafil, and use caution when getting up from a sitting or lying position. You may also want to avoid drinking large amounts of grapefruit juice, since it may increase the blood levels and effects of avanafil. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.